Plain-English translation of NCT06200103 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a radioactive medication called 177Lu-PSMA-617 for men with advanced prostate cancer that has stopped responding to hormone therapy. The study wants to know if patients who respond very well to this medication can safely take a break from treatment and wait until their cancer starts to come back, rather than continuing to receive regular doses. Researchers will compare how long patients in each group stay cancer-free and how they feel.
Once a patient responds well to this medication, doctors are unsure whether continuing regular treatments is better than pausing and restarting only if needed. This trial will help answer that question and may reduce unnecessary side effects while keeping patients protected from cancer progression.
You will receive the radioactive medication as an intravenous infusion every 6 weeks for up to 5 cycles, along with imaging scans to monitor how well it is working. After completing your initial treatment cycles and showing a strong response, you will be randomly assigned to either continue receiving the medication on schedule or to pause treatment and be closely monitored until your cancer begins to progress again. Throughout the trial, you will have regular blood draws, scans, and questionnaires about your quality of life, with visits occurring at Mayo Clinic Rochester.
AI-generated summary from trial data · Sep 5, 2026 · Not medical advice
United States